Intra-cranial administration of CTLA-4 and PD-1 immune checkpoint-inhibiting monoclonal antibodies in recurrent glioblastoma patients: a multi-cohort adaptive phase I clinical trial

Johnny Duerinck; A Vanbinst

Intra-cranial administration of CTLA-4 and PD-1 immune checkpoint-inhibiting monoclonal antibodies in recurrent glioblastoma patients: a multi-cohort adaptive phase I clinical trial

Research output: Unpublished contribution to conference › Poster

Original language	English
Publication status	Published - 2121
Event	26th Annual Meeting and Education Day of the Society for Neuro-Oncology - Boston, United States Duration: 18 Nov 2021 → 21 Nov 2021

Conference

Conference	26th Annual Meeting and Education Day of the Society for Neuro-Oncology
Country	United States
City	Boston
Period	18/11/21 → 21/11/21

Cite this

@conference{aa80640d163c4553affa4b2b0aabb983,

title = "Intra-cranial administration of CTLA-4 and PD-1 immune checkpoint-inhibiting monoclonal antibodies in recurrent glioblastoma patients: a multi-cohort adaptive phase I clinical trial",

author = "Johnny Duerinck and A Vanbinst",

year = "2121",

language = "English",

note = "null ; Conference date: 18-11-2021 Through 21-11-2021",

}

Intra-cranial administration of CTLA-4 and PD-1 immune checkpoint-inhibiting monoclonal antibodies in recurrent glioblastoma patients: a multi-cohort adaptive phase I clinical trial. / Duerinck, Johnny ; Vanbinst, A.

2121. Poster session presented at 26th Annual Meeting and Education Day of the Society for Neuro-Oncology
, Boston, United States.

Research output: Unpublished contribution to conference › Poster